Tibor Keler - Dec 7, 2022 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
EXECUTIVE VP & CSO
Signature
/s/ Samuel B. Martin, attorney-in-fact for Tibor Keler
Stock symbol
CLDX
Transactions as of
Dec 7, 2022
Transactions value $
-$575,740
Form type
4
Date filed
12/9/2022, 03:07 PM
Previous filing
Jun 17, 2022
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock, par value $0.001 per share Options Exercise $46.9K +16.9K +229.17% $2.78* 24.2K Dec 7, 2022 Direct
transaction CLDX Common Stock, par value $0.001 per share Sale -$623K -16.9K -69.62% $36.93 7.36K Dec 7, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (right to buy) Options Exercise $0 -16.9K -28.1% $0.00 43.1K Dec 7, 2022 Common Stock 16.9K $2.78 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.69 to $37.28 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
F2 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.